Biodesix, Inc. (NASDAQ:BDSX) Chairman John Patience Purchases 75,000 Shares of Stock

Biodesix, Inc. (NASDAQ:BDSX) Chairman John Patience bought 75,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was bought at an average cost of $1.38 per share, for a total transaction of $103,500.00. Following the acquisition, the chairman now owns 2,153,298 shares of the company’s stock, valued at approximately $2,971,551.24. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Biodesix Stock Performance

NASDAQ:BDSX opened at $1.33 on Thursday. The firm’s fifty day simple moving average is $1.70 and its 200-day simple moving average is $1.61. The company has a quick ratio of 3.28, a current ratio of 3.28 and a debt-to-equity ratio of 0.99. The stock has a market cap of $193.47 million, a PE ratio of -3.41 and a beta of 1.22. Biodesix, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $2.21.

Biodesix (NASDAQ:BDSX) last issued its earnings results on Friday, November 1st. The company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). Biodesix had a negative net margin of 66.84% and a negative return on equity of 369.89%. The company had revenue of $18.15 million for the quarter, compared to analyst estimates of $18.45 million. During the same period in the prior year, the business posted ($0.12) earnings per share. Analysts expect that Biodesix, Inc. will post -0.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BDSX has been the subject of a number of analyst reports. Scotiabank started coverage on shares of Biodesix in a research report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 price objective for the company. Craig Hallum started coverage on shares of Biodesix in a report on Friday, July 26th. They set a “buy” rating and a $3.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $3.06.

Hedge Funds Weigh In On Biodesix

Several hedge funds have recently bought and sold shares of the company. Essex Investment Management Co. LLC boosted its position in Biodesix by 1.4% during the first quarter. Essex Investment Management Co. LLC now owns 925,614 shares of the company’s stock worth $1,324,000 after purchasing an additional 12,669 shares in the last quarter. Opaleye Management Inc. boosted its position in shares of Biodesix by 7.7% in the 1st quarter. Opaleye Management Inc. now owns 534,657 shares of the company’s stock worth $765,000 after buying an additional 38,157 shares in the last quarter. CVI Holdings LLC purchased a new stake in shares of Biodesix in the 2nd quarter worth about $59,000. Perkins Capital Management Inc. grew its stake in Biodesix by 74.7% in the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock valued at $1,290,000 after acquiring an additional 310,000 shares during the last quarter. Finally, Farallon Capital Management LLC purchased a new position in Biodesix during the 2nd quarter valued at about $2,874,000. 20.96% of the stock is owned by hedge funds and other institutional investors.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.